Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 31, 2010 Brian Orelli	What Is Dendreon Worth? Now that's a good question, isn't it?
The Motley Fool August 8, 2011 Luke Timmerman	Dendreon Wounds Are Self-Inflicted, Not the Start of a Biotech Industry Virus Is Dendreon doomed?
The Motley Fool August 10, 2011 Jim Mueller	Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here.
The Motley Fool November 18, 2010 Brian Orelli	Worry-Free Dendreon? One step closer to national reimbursement from the Centers for Medicare and Medicaid Services to pay for its prostate cancer treatment Provenge.
The Motley Fool June 30, 2011 Brian Orelli	Dendreon Increases Potential Output, More to Come Los Angeles plant is approved.
The Motley Fool August 4, 2010 Brian Orelli	Dendreon Doubles Up The biotech enjoys twice as much revenue month over month.
The Motley Fool April 30, 2010 Brian Orelli	Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it?
The Motley Fool April 29, 2009 Brian Orelli	2 Lessons From Dendreon Traders beware.
The Motley Fool June 5, 2007 Brian Lawler	Dendreon Gets Its Funding Dendreon does a financing to secure its near-term future. Investors who fail to pay attention to relative valuations of the different stocks in the development-stage biotech space do so at their own peril.
The Motley Fool August 18, 2010 Travers & Greer	Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon?
BusinessWeek October 6, 2003 Gene G. Marcial	Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer.
The Motley Fool July 1, 2011 Luke Timmerman	Dendreon Sways Medicare to Pay for Prostate Cancer Drug The decision by Medicare is no surprise, but it does conclude a period of uncertainty about insurance reimbursement for its lone marketed product.
The Motley Fool May 9, 2007 Brian Lawler	Diagnosing Dendreon Postmortem The FDA issues an approvable letter for Dendreon's top compound. Investors, take note.
The Motley Fool November 16, 2007 Brian Lawler	Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note.
The Motley Fool September 28, 2010 Brian Orelli	It's Up! It's Down! It's Dendreon! The joys of biotech.
The Motley Fool September 22, 2010 Brian Orelli	A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead.
The Motley Fool November 3, 2011 David Williamson	Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100.
The Motley Fool June 22, 2009 Jim Mueller	Dendreon: Cash Out or Keep Riding Up? Given Dendreon's rise this year and Provenge's prospects, what should a prudent investor do?
The Motley Fool March 2, 2011 Brian Orelli	When Will Dendreon Make Money? Not for awhile ... it's a biotech thing.
The Motley Fool March 13, 2008 Brian Lawler	Dendreon Rolls the Dice The pharmaceutical amends a phase 3 study on its lead prostate cancer drug.
The Motley Fool May 10, 2006 Brian Lawler	Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note.
The Motley Fool November 23, 2011 Brian Orelli	I Was Wrong About Dendreon But maybe not in the long term.
The Motley Fool November 2, 2011 David Williamson	After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock.
The Motley Fool June 18, 2009 Daniel Harrison	Is Dendreon Just a Dot-Com Story at This Price? The stock has had a really good year, but now it may be time to lock in the gains.
The Motley Fool September 1, 2010 Brian Orelli	Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge.
The Motley Fool September 29, 2010 Brian Orelli	Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers.
The Motley Fool January 20, 2004 Dave Marino-Nachison	Dendreon Calls for Cash Investors don't mind a secondary offering when it comes on the coattails of good news.
The Motley Fool May 3, 2005 Karl Thiel	Is Dendreon a Rule Breaker? In working to bring the first therapeutic cancer vaccine to market, the company has faced numerous unknowns and challenges. At this stage, it has produced a fair bit of data that investors can use to size up the firm's prospects, but ultimately, you're either a believer or you're not.
The Motley Fool May 5, 2005 Salim Haji	Has Whole Foods Hit a "Tipping Point"? The company continues to defy skeptics as it turns in another stellar quarter and its rate of growth actually accelerates. There's no doubt that the stock is hot on Wall Street.
The Motley Fool June 19, 2009 Brian Orelli	Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk.
The Motley Fool August 4, 2010 Luke Timmerman	Dendreon Conference Call Notebook: The Tale of a Provenge Launch Ramp-Up What's working for Dendreon? How is its groundbreaking prostate cancer drug performing in its first few months on the market?
The Motley Fool August 29, 2011 Brian Orelli	We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply.
The Motley Fool May 3, 2011 Brian Orelli	Brakes Are Off at Dendreon Ramping up sales, one month at a time.
The Motley Fool June 14, 2006 Tim Beyers	Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's buying now? Chesapeake Energy... Dean Foods... Dendreon... NRG Energy... etc.
The Motley Fool July 1, 2011 Brian Orelli	Dendreon Is Drama-Free ... for Now For a drug that has had so much drama during its existence, the final decision by the Centers for Medicare and Medicaid Services to pay for Dendreon's prostate cancer treatment Provenge was pretty anticlimactic.
The Motley Fool November 30, 2010 Brian Orelli	Soros Is Buying Health Care. Should You? Some but not all of his picks look good to me.
The Motley Fool January 7, 2011 Brian Orelli	Dendreon Heads Across the Pond A pathway to Provenge approval in the EU.
The Motley Fool November 3, 2011 Brian Orelli	Modest Growth, Less-Than-Modest Stock Drop Dendreon's investors aren't happy.
The Motley Fool January 17, 2007 Brian Lawler	Dendreon in the Fast Lane The FDA speeds up review of Dendreon's leading drug candidate. Investors, take note.
The Motley Fool July 19, 2011 Alyce Lomax	Whole Foods' Cornucopia of Growth Whole Foods Market is one pricey grocery stock. But that dizzying valuation simply reflects its potential for impressive growth yet to come.
The Motley Fool August 4, 2011 Brian Orelli	Dendreon Down 65%! What's Next? What caused Dendreon's shocking collapse?
The Motley Fool May 4, 2009 Robert Steyer	Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success?
The Motley Fool July 1, 2010 Brian Orelli	Is Dendreon's Provenge in Trouble Before It Starts? Not! The Centers for Medicare & Medicaid Services questions the coverage of Provenge.
The Motley Fool April 14, 2009 Brian Orelli	Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge.
The Motley Fool November 10, 2006 Brian Lawler	Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note.
The Motley Fool April 4, 2008 Brian Lawler	A Few Thoughts on Dendreon Let's talk about the upcoming Dendreon study results.
The Motley Fool March 11, 2011 Brian Orelli	Sales Can Quadruple, More to Come Dendreon is still supply-constrained, but less than before.
The Motley Fool October 31, 2008 Brian Orelli	World's Scariest Stock: Dendreon The fear of the unknown makes investing scary, and things don't get much more unknown than the future of biotech company Dendreon.
The Motley Fool January 12, 2004 Dave Marino-Nachison	All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials.
The Motley Fool May 10, 2005 Charly Travers	Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in?